ImmunoGen, Inc. Signs Cancer Treatment Deal With Novartis AG; Immunogen to Receive $45 Million Upfront With Potential for $200 Million

ZURICH, Oct 11 (Reuters) - ImmunoGen Inc (IMGN.O) has signed a deal with Novartis (NOVN.VX) that lets the Swiss drugmaker develop anticancer treatments with fewer side effects, ImmunoGen said, giving the U.S. group another boost after recent positive data.